177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-10

AUTHORS

Daniel Hubble, Grace Kong, Michael Michael, Val Johnson, Shakher Ramdave, Rodney John Hicks

ABSTRACT

PURPOSE: The aim of this retrospective study was to determine whether patients with previous peptide receptor radionuclide therapy using high-activity (111)In-pentetreotide can be safely treated with (177)Lu-octreotate and whether addition of radiosensitising chemotherapy increases the toxicity of this agent. METHODS: Records of 27 patients (aged 17-75) who received 69 (median 3 per patient) (177)Lu-octreotate administrations, including 29 in conjunction with radiosensitising infusional 5-fluorouracil (5-FU) (n = 27), or capecitabine (n = 2), between October 2005 and July 2007 subsequent to 1-8 prior cycles of (111)In-pentetreotide therapy were analysed. Toxicity was assessed during and at 8-12 weeks post-treatment, with further long-term assessments including survival status reviewed till death or study close-out date of 1 November 2009. RESULTS: Reduction in blood counts was most marked following the first dose of (177)Lu-octreotate but at early follow-up the only major haematological toxicity was a single case of grade 4 lymphopaenia. Both the presence of bone metastases and the administration of chemotherapy tended to result in greater reduction in blood counts, but these differences did not reach statistical significance. On long-term follow-up, 16 patients (59%) are alive with median overall survival of 36 months (32-44 months from first (177)Lu-octreotate therapy). None of the recorded deaths was directly related to treatment toxicity. One patient had late grade 4 anaemia and thrombocytopaenia secondary to bone marrow failure from progressive infiltration by tumour. No other significant long-term haematological toxicities were recorded and no leukaemia was observed. No renal toxicity was observed on serial serum creatinine or radionuclide glomerular filtration rate (GFR) determination on initial or long-term follow-up. CONCLUSION: (177)Lu-octreotate is a safe and well-tolerated therapy for patients who have previously been treated with (111)In-pentetreotide and can be safely combined with radiosensitising chemotherapy. However, caution is recommended in patients with bone metastases. Significant late toxicities including bone marrow or renal failure, or leukaemia directly related to radionuclide therapy, did not occur in our series. More... »

PAGES

1869-1875

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4

DOI

http://dx.doi.org/10.1007/s00259-010-1483-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052925405

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20445977


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematologic Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroendocrine Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Octreotide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organometallic Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prodrugs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiation-Sensitizing Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Peptide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hubble", 
        "givenName": "Daniel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kong", 
        "givenName": "Grace", 
        "id": "sg:person.01122451566.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122451566.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Michael", 
        "givenName": "Michael", 
        "id": "sg:person.0673420201.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673420201.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnson", 
        "givenName": "Val", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ramdave", 
        "givenName": "Shakher", 
        "id": "sg:person.01236700166.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236700166.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hicks", 
        "givenName": "Rodney John", 
        "id": "sg:person.01121233254.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121233254.97"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/10.suppl_2.s31", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003031999"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.22.8510", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006418900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/snuc.2002.31769", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011217908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-007-0688-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016804176", 
          "https://doi.org/10.1007/s00259-007-0688-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-007-0688-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016804176", 
          "https://doi.org/10.1007/s00259-007-0688-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.2553", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019213889"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590050216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022226125", 
          "https://doi.org/10.1007/s002590050216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/snuc/2002.31025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031251521"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590100574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045446163", 
          "https://doi.org/10.1007/s002590100574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-002-1050-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045597456", 
          "https://doi.org/10.1007/s00259-002-1050-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-002-1050-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045597456", 
          "https://doi.org/10.1007/s00259-002-1050-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.beem.2007.01.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046292579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-002-0982-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046951944", 
          "https://doi.org/10.1007/s00259-002-0982-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590050476", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049195855", 
          "https://doi.org/10.1007/s002590050476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/cbr.2009.0641", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059242984"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/cbr.2009.0644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059242987"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1667/0033-7587(2003)159[0182:tnoadi]2.0.co;2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068194847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075047030", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076862224", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077094736", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082648707", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-10", 
    "datePublishedReg": "2010-10-01", 
    "description": "PURPOSE: The aim of this retrospective study was to determine whether patients with previous peptide receptor radionuclide therapy using high-activity (111)In-pentetreotide can be safely treated with (177)Lu-octreotate and whether addition of radiosensitising chemotherapy increases the toxicity of this agent.\nMETHODS: Records of 27 patients (aged 17-75) who received 69 (median 3 per patient) (177)Lu-octreotate administrations, including 29 in conjunction with radiosensitising infusional 5-fluorouracil (5-FU) (n = 27), or capecitabine (n = 2), between October 2005 and July 2007 subsequent to 1-8 prior cycles of (111)In-pentetreotide therapy were analysed. Toxicity was assessed during and at 8-12 weeks post-treatment, with further long-term assessments including survival status reviewed till death or study close-out date of 1 November 2009.\nRESULTS: Reduction in blood counts was most marked following the first dose of (177)Lu-octreotate but at early follow-up the only major haematological toxicity was a single case of grade 4 lymphopaenia. Both the presence of bone metastases and the administration of chemotherapy tended to result in greater reduction in blood counts, but these differences did not reach statistical significance. On long-term follow-up, 16 patients (59%) are alive with median overall survival of 36 months (32-44 months from first (177)Lu-octreotate therapy). None of the recorded deaths was directly related to treatment toxicity. One patient had late grade 4 anaemia and thrombocytopaenia secondary to bone marrow failure from progressive infiltration by tumour. No other significant long-term haematological toxicities were recorded and no leukaemia was observed. No renal toxicity was observed on serial serum creatinine or radionuclide glomerular filtration rate (GFR) determination on initial or long-term follow-up.\nCONCLUSION: (177)Lu-octreotate is a safe and well-tolerated therapy for patients who have previously been treated with (111)In-pentetreotide and can be safely combined with radiosensitising chemotherapy. However, caution is recommended in patients with bone metastases. Significant late toxicities including bone marrow or renal failure, or leukaemia directly related to radionuclide therapy, did not occur in our series.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00259-010-1483-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "name": "177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide", 
    "pagination": "1869-1875", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fc19567beae7d3f42c2327fb162c4270a37561a9a654f5cce2792363e7389a35"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20445977"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101140988"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-010-1483-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052925405"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-010-1483-4", 
      "https://app.dimensions.ai/details/publication/pub.1052925405"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113661_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00259-010-1483-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4'


 

This table displays all metadata directly associated to this object as RDF triples.

257 TRIPLES      21 PREDICATES      72 URIs      45 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-010-1483-4 schema:about N0187b5668c8946ccb32ae00af9cafa31
2 N06d1d6e27b3f480d87833ed6e002e209
3 N08a4ad10f19d48f7be7cd4067aa66d28
4 N15007963ea234c02aae3d4b868bbacb4
5 N1aa4b9e46b814994ab36313f3e3feb95
6 N287595488d91440d8d78141b8f70700b
7 N29be9f06e04b4f669cf667f00727b3c6
8 N30c57d0223df4fb29c9ffb77a98b684c
9 N35988d94be1940998b76a72648f05686
10 N646ad7c9aef4466cb5849812265b6a0f
11 N6a6d1297d2ff4c3ba7efb8c4b0775645
12 N79c00ce9156a4f9a8adc79ee92677f03
13 Na3296667524646e1a4ebe67687bcff2b
14 Na736f03e0d7a41948832c434a70b275d
15 Naaa281270925489b89bed3e2f14ec5d0
16 Nb193c883f31a49a59a3ef58072591d9e
17 Nb4d8d22b050f45bd8ef09f75d0b7c910
18 Nbdcf664f4e2e49078f1749c28fc3941c
19 Nc4a9e71174b4444898426eb2b681a3bc
20 Ncb5984816311418a99efb7ff9a846729
21 Nd2e37ada45164d29aabb06685cef84e9
22 Nd7fe0875e0884f65805c819a01f5c3e1
23 Nd86bc869a80241b39d2883d520c3d88b
24 Nf1c2e72f7fdf4462913ce508de877c02
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author N3ae4ff58b53c47219ba7dc1e7d040445
28 schema:citation sg:pub.10.1007/s00259-002-0982-3
29 sg:pub.10.1007/s00259-002-1050-8
30 sg:pub.10.1007/s00259-007-0688-7
31 sg:pub.10.1007/s002590050216
32 sg:pub.10.1007/s002590050476
33 sg:pub.10.1007/s002590100574
34 https://app.dimensions.ai/details/publication/pub.1075047030
35 https://app.dimensions.ai/details/publication/pub.1076862224
36 https://app.dimensions.ai/details/publication/pub.1077094736
37 https://app.dimensions.ai/details/publication/pub.1082648707
38 https://doi.org/10.1016/j.beem.2007.01.004
39 https://doi.org/10.1053/snuc.2002.31769
40 https://doi.org/10.1053/snuc/2002.31025
41 https://doi.org/10.1089/cbr.2009.0641
42 https://doi.org/10.1089/cbr.2009.0644
43 https://doi.org/10.1093/annonc/10.suppl_2.s31
44 https://doi.org/10.1200/jco.2007.15.2553
45 https://doi.org/10.1200/jco.2009.22.8510
46 https://doi.org/10.1667/0033-7587(2003)159[0182:tnoadi]2.0.co;2
47 schema:datePublished 2010-10
48 schema:datePublishedReg 2010-10-01
49 schema:description PURPOSE: The aim of this retrospective study was to determine whether patients with previous peptide receptor radionuclide therapy using high-activity (111)In-pentetreotide can be safely treated with (177)Lu-octreotate and whether addition of radiosensitising chemotherapy increases the toxicity of this agent. METHODS: Records of 27 patients (aged 17-75) who received 69 (median 3 per patient) (177)Lu-octreotate administrations, including 29 in conjunction with radiosensitising infusional 5-fluorouracil (5-FU) (n = 27), or capecitabine (n = 2), between October 2005 and July 2007 subsequent to 1-8 prior cycles of (111)In-pentetreotide therapy were analysed. Toxicity was assessed during and at 8-12 weeks post-treatment, with further long-term assessments including survival status reviewed till death or study close-out date of 1 November 2009. RESULTS: Reduction in blood counts was most marked following the first dose of (177)Lu-octreotate but at early follow-up the only major haematological toxicity was a single case of grade 4 lymphopaenia. Both the presence of bone metastases and the administration of chemotherapy tended to result in greater reduction in blood counts, but these differences did not reach statistical significance. On long-term follow-up, 16 patients (59%) are alive with median overall survival of 36 months (32-44 months from first (177)Lu-octreotate therapy). None of the recorded deaths was directly related to treatment toxicity. One patient had late grade 4 anaemia and thrombocytopaenia secondary to bone marrow failure from progressive infiltration by tumour. No other significant long-term haematological toxicities were recorded and no leukaemia was observed. No renal toxicity was observed on serial serum creatinine or radionuclide glomerular filtration rate (GFR) determination on initial or long-term follow-up. CONCLUSION: (177)Lu-octreotate is a safe and well-tolerated therapy for patients who have previously been treated with (111)In-pentetreotide and can be safely combined with radiosensitising chemotherapy. However, caution is recommended in patients with bone metastases. Significant late toxicities including bone marrow or renal failure, or leukaemia directly related to radionuclide therapy, did not occur in our series.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree false
53 schema:isPartOf N00e6a92d14674f2e874deb0388692552
54 N6f310cd84c6642b7837449955862d3f8
55 sg:journal.1297401
56 schema:name 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
57 schema:pagination 1869-1875
58 schema:productId N12f2179059cf4b568de0c7c45456ce72
59 N350ef48881b842ef8d9b931a14794056
60 N364e72dbc7bb4684b4287e2b93a69bb1
61 N4f82e84d1a3a498bb2ab2d634efffde9
62 N922145a25cde44318923182e684a2529
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052925405
64 https://doi.org/10.1007/s00259-010-1483-4
65 schema:sdDatePublished 2019-04-11T10:33
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher Ne199579fd97040c4bcc4916ae5a09aa9
68 schema:url http://link.springer.com/10.1007%2Fs00259-010-1483-4
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N00e6a92d14674f2e874deb0388692552 schema:volumeNumber 37
73 rdf:type schema:PublicationVolume
74 N0187b5668c8946ccb32ae00af9cafa31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Female
76 rdf:type schema:DefinedTerm
77 N024d0e2877d24d7d95e725e696673f2b rdf:first sg:person.0673420201.89
78 rdf:rest N62d63e14d59e4a04a66acf486deefb7e
79 N06d1d6e27b3f480d87833ed6e002e209 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Follow-Up Studies
81 rdf:type schema:DefinedTerm
82 N08a4ad10f19d48f7be7cd4067aa66d28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Deoxycytidine
84 rdf:type schema:DefinedTerm
85 N12f2179059cf4b568de0c7c45456ce72 schema:name nlm_unique_id
86 schema:value 101140988
87 rdf:type schema:PropertyValue
88 N15007963ea234c02aae3d4b868bbacb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Aged
90 rdf:type schema:DefinedTerm
91 N1aa4b9e46b814994ab36313f3e3feb95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Capecitabine
93 rdf:type schema:DefinedTerm
94 N287595488d91440d8d78141b8f70700b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Fluorouracil
96 rdf:type schema:DefinedTerm
97 N29be9f06e04b4f669cf667f00727b3c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Organometallic Compounds
99 rdf:type schema:DefinedTerm
100 N30c57d0223df4fb29c9ffb77a98b684c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Survival Analysis
102 rdf:type schema:DefinedTerm
103 N350ef48881b842ef8d9b931a14794056 schema:name pubmed_id
104 schema:value 20445977
105 rdf:type schema:PropertyValue
106 N35988d94be1940998b76a72648f05686 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Radiation-Sensitizing Agents
108 rdf:type schema:DefinedTerm
109 N364e72dbc7bb4684b4287e2b93a69bb1 schema:name doi
110 schema:value 10.1007/s00259-010-1483-4
111 rdf:type schema:PropertyValue
112 N3ae4ff58b53c47219ba7dc1e7d040445 rdf:first Ne4ee7d1da1f748768474c9543ed93a0f
113 rdf:rest N55a39eab8eec4da1bac05a7a4cb11458
114 N4ee895e470704707a70463e22e01115a schema:affiliation https://www.grid.ac/institutes/grid.1055.1
115 schema:familyName Johnson
116 schema:givenName Val
117 rdf:type schema:Person
118 N4f82e84d1a3a498bb2ab2d634efffde9 schema:name readcube_id
119 schema:value fc19567beae7d3f42c2327fb162c4270a37561a9a654f5cce2792363e7389a35
120 rdf:type schema:PropertyValue
121 N5355c82113a942d8a84cf267bb4db553 rdf:first sg:person.01121233254.97
122 rdf:rest rdf:nil
123 N55a39eab8eec4da1bac05a7a4cb11458 rdf:first sg:person.01122451566.24
124 rdf:rest N024d0e2877d24d7d95e725e696673f2b
125 N62d63e14d59e4a04a66acf486deefb7e rdf:first N4ee895e470704707a70463e22e01115a
126 rdf:rest N81bf7a21e45b4298801f27de9586e63a
127 N646ad7c9aef4466cb5849812265b6a0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Kidney
129 rdf:type schema:DefinedTerm
130 N6a6d1297d2ff4c3ba7efb8c4b0775645 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Hematologic Tests
132 rdf:type schema:DefinedTerm
133 N6f310cd84c6642b7837449955862d3f8 schema:issueNumber 10
134 rdf:type schema:PublicationIssue
135 N79c00ce9156a4f9a8adc79ee92677f03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Time Factors
137 rdf:type schema:DefinedTerm
138 N81bf7a21e45b4298801f27de9586e63a rdf:first sg:person.01236700166.42
139 rdf:rest N5355c82113a942d8a84cf267bb4db553
140 N922145a25cde44318923182e684a2529 schema:name dimensions_id
141 schema:value pub.1052925405
142 rdf:type schema:PropertyValue
143 Na3296667524646e1a4ebe67687bcff2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Adult
145 rdf:type schema:DefinedTerm
146 Na736f03e0d7a41948832c434a70b275d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Receptors, Peptide
148 rdf:type schema:DefinedTerm
149 Naaa281270925489b89bed3e2f14ec5d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Middle Aged
151 rdf:type schema:DefinedTerm
152 Nb193c883f31a49a59a3ef58072591d9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Humans
154 rdf:type schema:DefinedTerm
155 Nb4d8d22b050f45bd8ef09f75d0b7c910 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Prodrugs
157 rdf:type schema:DefinedTerm
158 Nbdcf664f4e2e49078f1749c28fc3941c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Adolescent
160 rdf:type schema:DefinedTerm
161 Nc4a9e71174b4444898426eb2b681a3bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Retrospective Studies
163 rdf:type schema:DefinedTerm
164 Ncb5984816311418a99efb7ff9a846729 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Male
166 rdf:type schema:DefinedTerm
167 Nd2e37ada45164d29aabb06685cef84e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Antineoplastic Combined Chemotherapy Protocols
169 rdf:type schema:DefinedTerm
170 Nd7fe0875e0884f65805c819a01f5c3e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Young Adult
172 rdf:type schema:DefinedTerm
173 Nd86bc869a80241b39d2883d520c3d88b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Octreotide
175 rdf:type schema:DefinedTerm
176 Ne199579fd97040c4bcc4916ae5a09aa9 schema:name Springer Nature - SN SciGraph project
177 rdf:type schema:Organization
178 Ne4ee7d1da1f748768474c9543ed93a0f schema:affiliation https://www.grid.ac/institutes/grid.1055.1
179 schema:familyName Hubble
180 schema:givenName Daniel
181 rdf:type schema:Person
182 Nf1c2e72f7fdf4462913ce508de877c02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Neuroendocrine Tumors
184 rdf:type schema:DefinedTerm
185 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
186 schema:name Medical and Health Sciences
187 rdf:type schema:DefinedTerm
188 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
189 schema:name Clinical Sciences
190 rdf:type schema:DefinedTerm
191 sg:journal.1297401 schema:issn 1619-7070
192 1619-7089
193 schema:name European Journal of Nuclear Medicine and Molecular Imaging
194 rdf:type schema:Periodical
195 sg:person.01121233254.97 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
196 schema:familyName Hicks
197 schema:givenName Rodney John
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121233254.97
199 rdf:type schema:Person
200 sg:person.01122451566.24 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
201 schema:familyName Kong
202 schema:givenName Grace
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122451566.24
204 rdf:type schema:Person
205 sg:person.01236700166.42 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
206 schema:familyName Ramdave
207 schema:givenName Shakher
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236700166.42
209 rdf:type schema:Person
210 sg:person.0673420201.89 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
211 schema:familyName Michael
212 schema:givenName Michael
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673420201.89
214 rdf:type schema:Person
215 sg:pub.10.1007/s00259-002-0982-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046951944
216 https://doi.org/10.1007/s00259-002-0982-3
217 rdf:type schema:CreativeWork
218 sg:pub.10.1007/s00259-002-1050-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045597456
219 https://doi.org/10.1007/s00259-002-1050-8
220 rdf:type schema:CreativeWork
221 sg:pub.10.1007/s00259-007-0688-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016804176
222 https://doi.org/10.1007/s00259-007-0688-7
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s002590050216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022226125
225 https://doi.org/10.1007/s002590050216
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/s002590050476 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049195855
228 https://doi.org/10.1007/s002590050476
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s002590100574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045446163
231 https://doi.org/10.1007/s002590100574
232 rdf:type schema:CreativeWork
233 https://app.dimensions.ai/details/publication/pub.1075047030 schema:CreativeWork
234 https://app.dimensions.ai/details/publication/pub.1076862224 schema:CreativeWork
235 https://app.dimensions.ai/details/publication/pub.1077094736 schema:CreativeWork
236 https://app.dimensions.ai/details/publication/pub.1082648707 schema:CreativeWork
237 https://doi.org/10.1016/j.beem.2007.01.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046292579
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1053/snuc.2002.31769 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011217908
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1053/snuc/2002.31025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031251521
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1089/cbr.2009.0641 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059242984
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1089/cbr.2009.0644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059242987
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1093/annonc/10.suppl_2.s31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003031999
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1200/jco.2007.15.2553 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019213889
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1200/jco.2009.22.8510 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006418900
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1667/0033-7587(2003)159[0182:tnoadi]2.0.co;2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068194847
254 rdf:type schema:CreativeWork
255 https://www.grid.ac/institutes/grid.1055.1 schema:alternateName Peter MacCallum Cancer Centre
256 schema:name Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew’s Place, 3002, East Melbourne, VIC, Australia
257 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...